Establishing new use criteria led to an 86% reduction in the utilization of sugammadex with no appreciable impact on measured outcomes.
Andrea Reed, PharmD, MBA, BCPS, DPLA
Advertisement
Articles by Andrea Reed, PharmD, MBA, BCPS, DPLA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
A Common Virus May Hold New Clues to Lupus
2
Managing Safety and Supportive Care With Pluvicto: Insights From the PSMAddition Trial
3
FDA Approves Poherdy, First Biosimilar to Perjeta, For HER2 Breast Cancer Indications
4
Study Finds Similar Outcomes Between hMPV and RSV Hospitalizations
5
